Everolimus

• Individualized everolimus therapy in metastatic breast cancer Pending
  2023-505590-33-06 Phase II 1 country Orszagos Onkologiai Intezet
• Repurposing Everolimus to enhance musculoskeletal Vitality and Ageing in The Elderly (RENOVATE) Pending
  2023-509838-19-00 Phase II 1 country Odense University Hospital
• A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APP… Pending
  2024-516570-30-00 Phase II 5 countries Centre Hospitalier De Versailles
• Safety and efficacy of steering of immunosuppression based on BKPyV-specific T cells in case of BK Polyomavirus (BKPyV) DNAemia after kidney… Pending
  2024-517219-56-00 Phase IV 1 country Paediatrisches Forschungsnetzwerk gGmbH; PROFIL Institut fuer Stoffwechselforsch…
• Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma… Pending
  2025-524031-39-00 Phase I (Other) 1 country Instytut Pomnik Centrum Zdrowia Dziecka
• A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec… Recruiting
  2024-512926-27-00 Phase III 7 countries Medica Scientia Innovation Research S.L.; Stemline Therapeutics Inc.
• Immunosuppression regimen reduction in kidney transplantation recipients admitted to the intensive care unit in the setting of septic shock … Recruiting
  2024-518493-14-00 Phase II/III 1 country Les Hopitaux Universitaires De Strasbourg
• A Phase 2/3 clinical trial with zanzalintinib versus everolimus Recruiting
  2025-521043-20-00 Phase II/III 8 countries Exelixis Inc.
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan… Recruiting
  2025-520566-22-00 Phase III 14 countries Pfizer Inc.
• Resistance training and rapamycin to enhance bone formation in postmenopausal women (STRONGBONE) Recruiting
  2024-520372-10-00 Phase II 1 country Odense University Hospital
• zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric ra… Recruiting
  2023-509598-22-01 Phase IV 1 country Champalimaud Clinical Centre; Rita Fior
• Lutathera for the treatment of recurrent Meningioma (LUMEN-1) Recruiting
  2024-513443-93-00 Phase II 8 countries Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europ…
• Evaluation of the addition of Everolimus to 177Lu-DOTATATE in the treatment of grades 2 and 3 refractory meningioma: a phase IIb clinical tr… Recruiting
  2023-508400-38-00 Phase II 1 country CHRU De Nancy
• Targeting mTOR with everolimus and/or physical training for preventing postmenopausal bone loss and accelerated skeletal aging. The RapaLoad… Recruiting
  2023-508093-28-00 Phase II 1 country Odense University Hospital
• Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects wi… Recruiting
  2023-509334-19-00 Phase III 4 countries Rayzebio Inc.
• 177Lu-edotreotide compared to everolimus in neuroendocrine tumors of the lung and thymus Recruiting
  2022-502154-13-00 Phase III 4 countries Grupo Espanol De Tumores Neuroendocrinos
• Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial) Recruiting
  2022-502703-30-00 Phase IV 2 countries Antwerp University Hospital
• EVIDENT Recruiting
  2023-510092-62-00 Phase II 1 country Oslo University Hospital HF
• Efficiency of everolimus for the treatment of kidney transplanted patients presenting a rejection Recruiting
  2024-513814-37-00 Phase IV 1 country Hospices Civils De Lyon
• An experimental study in adults and adolescents who underwent stem cell transplantation and developed a Graft versus Host Disease after ster… Recruiting
  2023-505737-26-00 Phase III 4 countries Medac Gesellschaft fuer klinische Spezialprapaerate mbH
• AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Recruiting
  2024-514791-40-00 Phase I/II 5 countries Institut Gustave Roussy
• Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication: BIOMEDE 2.0 Recruiting
  2023-506027-29-00 Phase III 4 countries Institut Gustave Roussy
• A Study to Evaluate the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician’s Choice of Endocrine Therapy Plus E… Ended
  2023-506821-12-00 Phase III 4 countries Genentech Inc.
• Lutetium (177Lu) Edotreotide versus Best Standard of Care in Well-differentiated Aggressive Grade 2 and Grade 3 Gastroenteropancreatic Neuro… Ended
  2024-510812-64-00 Phase III 5 countries ITM Solucin GmbH

Showing 1–24 of 31 trials